Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Xeloda – Treatment for Metastatic Colorectal Cancer - Clinical Trials Arena
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
Xeloda – Treatment for Metastatic Colorectal Cancer - Clinical Trials Arena
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer | NEJM
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open‐label, single‐arm, noncomparative trial - Chen - 2018 -
Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study - ScienceDirect
Avastin with Xeloda as a first-line treatment for metastatic breast cancer bc_en | PDF
Cancers | Free Full-Text | Adjuvant Chemotherapy for Stage III Colon Cancer
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
Avastin® (bevacizumab) Dosing | MCRC Treatment
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised ...
1175-Colorectal metastatic capecitabine and beVACizumab | eviQ
Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma | Semantic Scholar
New Treatment Options for Colorectal Cancer
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook - Cancer Treatment Reviews
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer | British Journal of Cancer